Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
Press Releases
Glenmark Pharmaceuticals Ltd  
March 20, 2025

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)

MAHWAH, N.J., March 20, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic

avatar profile Olean Times Herald

Olean Times Herald


Local & Social